Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Apazone”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 109 records · Page 6Linked to original sources
PubMed1976

A comparative pilot study of azapropazone and indomethacin in the treatment of psoriatic arthritis and Reiter's disease.

A double-blind crossover study to compare 1200 mg. azapropazone per day with 100 mg. indomethacin per day was carried out on 34 patients with psoriatic arthritis and 16 patients with Reiter's disease. The same comparison was initiated in 8 additional patients but withdrawn in 3 cases because of side-effects to indomethacin, in 2 cases because of side-effects to azapropazone, and in the 3 remaining cases for other stated reasons. The results of the study showed no overall difference between the treatment results of azapropazone and indomethacin, but azapropazone seemed to be more effective in cases with psoriatic arthritis and indomethacin in cases with Reiter's disease. Indomethacin caused more side-effects than azapropazone. Neither drug seemed to influence the skin manifestations of either disease.

Adult↗
PubMed1976

A comparative study of azapropazone and indomethacin in the treatment of rheumatoid arthritis.

A double-blind crossover trial in 50 patients with rheumatoid arthritis was carried out to compare the clinical effectiveness of 800 mg. azapropazone per day with 100 mg. indomethacin per day. Blood plasma concentrations of azapropazone were also studied in 10 patients. Patients received both drugs for a 3-week period, the order of treatment being determined at random. Although there were no marked differences in any of the objective measurements, patients assessments of response to and preference for each drug treatment period suggested that azapropazone produced significant improvement compared to that with indomethacin. Plasma levels of azapropazone remained remarkably constant for each patient. Side-effects with both drugs were mild and transient, and there were no marked variations from normal in any of the laboratory parameters measured.

Adult↗
PubMed1976

Prolonged treatment with azapropazone.

In an open study of 40 patients with chronic rheumatoid polyarthritis, azapropazone was given alone in daily doses between 1200 mg. and 1800 mg. over a period of 6 months. Six patients were withdrawn, 2 because of side-effects (1 with an allergic-type rash; 1 with ankle oedema) and 4 because azapropazone alone did not provide adequate control of their pain and discomfort. Objective assessments showed that 18 patients had a 'good' or 'very good' response to treatment, and a further 16 showed moderate improvement. These findings were supported by the patients' subjective assessment of the change in their condition from the start of the trial. In addition, 22 patients showed a significant decrease in erythrocyte sedimentation rate. There was no evidence of adverse effects on any of the haematological and biochemical parameters measured, and the incidence of side-effects was low.

Adult↗
PubMed1976

Long-term use of azapropazone in rheumatoid conditions.

In an open assessment of azapropazone, 51 patients with rheumatoid disorders, mainly rheumatoid arthritis, were treated continuously for periods up to 3 years (range 2 weeks to 38 months). Treatment was interrupted or discontinued in 9 patients for various reasons. Initial dosage was 1200 mg. daily, but this was usually reduced after a few months to a maintenance level of 900 mg. daily. An overall assessment of patient response at the end of the study period indicated that only 4 (7.8%) of the 51 patients failed to obtain satisfactory relief during treatment: 28 (54.6%) showed objective signs of improvement, such as reduced joint swelling and stiffness, as well as subjective evidence of symptom relief, and a further 19 patients (37.3%) reported an equivocal analgesic effect with azapropazone. Few side-effects were reported, mainly mild gastralgia and nausea, and routine laboratory investigations throughout the long-term study revealed no abnormalities in the blood picture, liver or renal function or coagulation factors. There was also no evidence of any interaction between azapropazone and other drugs used concomitantly.

Adult↗
PubMed1976

Gastro-intestinal bleeding in patients with rheumatoid arthritis: the effects of azapropazone treatment.

A comparative study was carried out, using the Cr51 red blood cell labelling method, to assess the amount of gastro-intestinal blood loss in 20 rheumatoid arthritis patients taking either 600 mg. or 1200 mg. azapropazone daily. The results demonstrate that azapropazone does not produce greater than normal gastro-intestinal bleeding, that the volume of faecal blood loss is not dose-related, and there would not appear to be any correlation between blood loss and the occasional mild gastro-intestinal side-effects reported in a few patients. These results compared favourably with those obtained previously by the investigators in a similar group of patients taking 3 g. aspirin per day.

Adult↗
PubMed1976

Azapropazone - its place in the management of rheumatoid conditions.

The authors review the trials carried out on azapropazone in rheumatoid arthritis and other rheumatoid conditions. They comment that in terms of efficacy azapropazone would appear to be a useful non-steroidal anti-inflammatory analgesic which compares favourably with other established antirheumatic agents against which it has been tested. Its main advantages are its low incidence of side-effects and the fact that in the majority of the trials reported azapropazone treatment was preferred by patients to that with other agents.

Apazone↗
PubMed1976

Comparison of azapropazone and naproxen in rheumatoid arthritis.

A double-blind crossover trial was carried out in 15 patients with definite rheumatoid arthritis to compare the effectiveness of 1200 mg azapropazone daily and 750 mg naproxen daily, each drug being given for 2 weeks. Patients also received placebo therapy before and between the two treatment periods. The results of subjective and objective assessments showed that both drugs were significantly superior to placebo, but no significant difference could be demonstrated between the two drugs.

Adolescent↗
PubMed1981

Clinical therapeutic trial of aspirin and azapropazone in rheumatoid arthritis when prescribed singly and in combination.

A double-blind, crossover trial was carried out to assess the clinical efficacy of 3.6 g aspirin, 1200 mg azapropazone and the two drugs together in 24 adult patients with classical or definite rheumatoid disease. Pain score, morning stiffness and patients' assessment of pain were significantly improved for each drug regimen when compared to placebo. There was no significant difference among the individual drug regimens. Azapropazone was the best drug regimen in terms of improving pain score, morning stiffness and patient assessment of pain, but this was not statistically significant. It is concluded that there is no justification for prescribing aspirin with azapropazone in patients with rheumatoid disease.

Adult↗
PubMed1984

Azapropazone in arthritis: a long-term treatment.

A long-term open assessment of azapropazone (900 mg to 1200 mg daily) was carried out in 51 patients suffering from osteoarthritis for periods of up to 1 year. Of these patients, 70% completed 9 to 12 months of treatment. Clinical assessments were made before and during the study of pain on motion or weight bearing, night pain, functional activity, morning stiffness, doctor's overall assessment, patients' overall assessment, and details of side-effects recorded. There were statistically significant improvements in the mean rating scores for each of the clinical assessments and these became apparent at 1 month, maximal at 3 to 6 months and persisted at the same level to the end of the trial. There were no side-effects recorded at any period of the trial in 30 (59%) patients. When side-effects did occur they were mild in 12 (24%), moderate in 3 (6%) and severe in 6 (12%) patients. The most frequent side-effects were related to the gastro-intestinal tract and gastric pain occurred in 7 (14%) patients, whilst rash or eczema occurred in 4 (8%) patients. It was concluded that, for the patients in the trial, long-term treatment with azapropazone was a useful and effective procedure.

Adult↗
PubMed1990

The effect of prostaglandin synthetase inhibitors on human preovulatory follicular fluid prostaglandin, thromboxane, and leukotriene concentrations.

This study evaluates the eicosanoid concentration in luteinized unruptured follicles (LUFs) on the ovaries of patients who had been treated with inhibitors of prostaglandin synthetase. Indomethacin, bromfenac, or azapropazone (or a placebo) was administered orally to 41 women during the periovulatory period. Follicular development was monitored by serial ultrasound examinations, and the onset of ovulation was regulated by an injection of hCG. Follicular fluid was aspirated during sterilization by minilaparotomy, which was performed just before the expected time of ovulation. Prostaglandin E2 and PGF2 alpha levels in the fluid were significantly reduced by indomethacin and bromfenac compared to those after placebo treatment. Bromfenac also reduced the follicular fluid leukotriene B4 level. Therefore, the development of luteinized unruptured follicles after treatment with nonsteroidal antiinflammatory drugs appears to be associated with a significant decrease in the synthesis of ovarian eicosanoids.

Adult↗
PubMed2004

Screening major binding sites on human serum albumin by affinity capillary electrophoresis.

A screening method is described for determining whether a drug or small solute has significant interactions at the two major binding sites on human serum albumin (HSA). This method uses affinity capillary electrophoresis (ACE) to perform a mobility shift assay, where the solute of interest is injected in both the presence of pH 7.4, 0.067 M phosphate buffer, and the same buffer containing a known concentration of HSA. Dextran is also used in the running buffer to adjust the mobility of HSA. Two types of modified HSA are used in this assay. The first is modified with 2-hydroxy-5-nitrobenzyl bromide (HNB), which selectively blocks HSA's warfarin-azapropazone site. The second type of HSA is modified with tetranitromethane (TNM), which decreases binding at the indole-benzodiazepine site. By comparing the mobility of a solute in the presence of these two modified forms of HSA vs normal HSA, it is possible to detect solute interactions at these binding sites. This approach is illustrated using warfarin and ibuprofen as examples of test solutes.

2-Hydroxy-5-nitrobenzyl Bromide↗
PubMed1991

A controlled trial of azapropazone in tinnitus.

A single-blind placebo-controlled trial of azapropazone, a non-steroidal anti-inflammatory drug, is presented in 10 patients with tinnitus. Seventeen variables were assessed by questionnaire and six by a daily diary. In none of these was there a significant difference between placebo and drug. A larger trial is probably therefore not justified.

Apazone↗
PubMed1986

Reversible non-oliguric impairment of renal function during azapropazone treatment.

An impairment of the renal function was observed in three patients who received azapropazone for various rheumatic disorders with simultaneous hyperuricaemia. A distinct increase in serum creatinine occurred in all patients. In one case the renal biopsy suggested a hypersensitivity reaction with a consequent acute tubulo-interstitial nephritis as the mechanism of the impaired renal function. The renal insufficiency was reversible in all cases after the withdrawal of azapropazone.

Acute Disease↗
PubMed1977

Azapropazone induced bullous drug eruptions.

Azapropazone is a new, powerful, antiinflammatory analgesic. Initial trails have confirmed its efficacy as an antirheumatic agent, with a low incidence of adverse reactions. Recently the authors have seen two patients, each of whom developed a distinctive but clinically dissimilar, bizarre, bullous eruption after taking this drug. A brief account of these cases has been published elsewhere (1).

Apazone↗
PubMedDate not supplied

Repeated cyclosporine therapy of peripheral arthritis associated with ankylosing spondylitis.

BACKGROUND: A case history of a patient with ankylosing spondylitis and peripheral arthritis unresponsive to the conventional drug therapy, but successfully controlled by the use of cyclosporin. MATERIAL AND METHODS: In a 68 years old female patient with a 36 years history of typical ankylosing spondylitis a peripheral polyarthritis (hands, feet, wrists, and knees) developed. The patient did not suffer any other disease known to cause secondary spondylitis (psoriasis, inflammatory, bowel, disease). After the unsuccessful use of non-steroidal antiinflammatory drugs a combination therapy with cyclosporin (4 mg/kg/day) and azapropazone (300 mg t.i.d.) was introduced. RESULTS: Clinical improvement was achieved after 6 months of combined therapy, the polyarthritis completely resolved after one year. Therefore cyclosporin was discontinued. After one year the polyarthritis reappeared therefore the cyclosporin therapy was reinstituted with success. CONCLUSION: Cyclosporin has proved consistently effective in our case to control the peripheral arthritis associated with ankylosing spondylitis.

Aged↗